Fed’s new power struggle: Kevin Warsh’s first-day tests collide with Trump’s $1.5T budget and FDA shake-up

On May 13, 2026, the U.S. political and financial establishment moved on multiple fronts at once: the Senate confirmed Kevin Warsh to the Federal Reserve’s Board of Governors, while Wall Street and Washington prepared for how Warsh would respond to political pressure and whether he would align the Fed with major changes he favors. In parallel, reporting highlighted that Pete Hegseth defended a proposed $1.5 trillion budget before Congress, signaling an aggressive fiscal agenda that could shape the macro backdrop for rates, inflation expectations, and Treasury issuance. Separately, President Donald Trump said Marty Makary is out as Commissioner of the Food and Drug Administration, and the resignation was framed as part of a broader pattern of high-profile departures in 2026. Taken together, the cluster points to a coordinated push to reshape both monetary and regulatory policy levers during a period when markets are highly sensitive to credibility and institutional independence. Strategically, the key geopolitical angle is institutional power: the Fed’s governance and the FDA’s regulatory posture both affect how quickly the U.S. can respond to economic shocks, manage inflationary impulses, and maintain confidence in rule-based policy. Warsh’s confirmation raises questions about whether the central bank will be pulled toward a more politically aligned policy stance, which would matter for global capital flows because the U.S. dollar and U.S. rates are the anchor for much of the world’s risk pricing. Meanwhile, the $1.5T budget defense suggests fiscal expansion or re-prioritization that could complicate the Fed’s job, especially if deficits widen and bond supply increases. The FDA leadership change adds another layer: regulatory direction can influence pharmaceutical approvals, public health compliance, and the credibility of U.S. oversight—factors that also affect investor sentiment in healthcare and biotech. Market implications are likely to concentrate in interest-rate and credit-sensitive segments. If Warsh’s policy preferences translate into expectations of faster easing, tighter financial conditions could loosen, supporting duration-sensitive assets, but any perception of reduced Fed independence would also raise term-premium risk and push volatility higher; the net effect would depend on how quickly markets price credibility. The fiscal narrative around a $1.5T budget can affect Treasury yields and the curve, with potential spillovers into mortgage rates, bank funding costs, and risk assets that rely on stable discount rates. On the healthcare side, the Makary exit can move expectations for FDA enforcement and approval timelines, influencing biotech and pharma sentiment, though the immediate magnitude is likely smaller than the rate channel. Overall, the cluster increases the probability of cross-asset repricing—rates, USD, and healthcare equities—driven by policy credibility rather than by a single economic data release. What to watch next is whether Warsh’s early communications and voting record align with the “major changes” he favors, and whether Fed leadership signals insulation from political pressure. Congress’s reaction to the $1.5T budget—especially committee markups, vote margins, and any language tied to deficit targets—will be a near-term trigger for Treasury supply expectations and rate volatility. For the FDA, the appointment of an interim commissioner and the stated priorities for enforcement and review capacity will determine whether markets interpret the leadership change as continuity or a regulatory reset. Key indicators include changes in front-end rate expectations, the 2-year and 10-year Treasury yield spread, USD strength versus a basket of currencies, and healthcare sector relative performance; escalation risk rises if policy signals suggest a direct tug-of-war over central bank independence or if budget negotiations threaten funding timelines. The timeline for escalation is short—days to weeks—because Warsh’s first-day posture and the immediate congressional budget process can quickly reshape expectations.

Geopolitical Implications

• 01

  Potential politicization of Fed governance could affect global dollar funding conditions and risk pricing.

• 02

  Fiscal expansion signals can tighten the policy mix, forcing the Fed to balance credibility against growth and inflation pressures.

• 03

  FDA leadership turnover can reshape regulatory credibility in healthcare, influencing investment flows into U.S. life sciences.

Key Signals

• —Warsh’s early statements and voting alignment with preferred “major changes”.
• —Congressional progress and language tied to deficit targets in the $1.5T budget.
• —Interim FDA leadership appointment and immediate enforcement/review-capacity priorities.
• —Front-end rate expectations, 2Y/10Y spread, and USD strength reactions.
• —Healthcare sector relative performance versus broad equities.